Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.
Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.62 by 46.77 percent. This is a 7.06 percent increase over earnings of $0.85 per share from
American Airlines Group Inc. (NASDAQ: AAL) stock moves upward Wednesday following travel sector talks at the White House and a pause in crude oil price rallies.
Carnival stock declined 3.51% to $23.89, significantly underperforming the S&P 500's 0.33% loss. The cruise operator has fallen 10.97% over the past month while the broader market gained 3.87%. Analysts expect upcoming earnings of $1.36 per share (down 4.9% YoY) with revenue of $8.36 billion (up 2.59% YoY). Carnival holds a Zacks Rank of #3 (Hold) with a Forward P/E of 11.1, trading at a discount to its industry average.